GenoMed Finds Two Genes Linked to Common Cancers
Posted on: Thursday, 13 January 2005, 09:00 CST
ST. LOUIS, Jan. 13 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM(TM) (Disease Management) company which finds disease-causing genes in order to improve patient outcomes, announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
The first gene, involved in copying DNA, was linked specifically to pancreatic and ovarian cancers, which are notoriously hard to diagnose at an early stage. It could help in the early diagnosis of patients at high risk for these cancers, as well as serve as a possible drug target for treatment of these poorly treatable diseases.
The second gene codes for a scaffolding protein involved in building protein networks inside the cell. It was linked to all six common cancers (lung, colon, breast, prostate, ovarian, and pancreatic), and may lead to new broad-spectrum chemotherapeutic agents.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "We still have to validate our initial results. The best news is that our conveyor belt for finding new disease genes is up and running. We're now testing one or two genes a week in our own lab, and will soon be testing tens of thousands of genes at a time through our collaboration with Genome Quebec."
About GenoMed
GenoMed is leading the clinical revolution which knowledge of disease genes has already made possible. GenoMed is currently marketing its protocols to prevent the need for kidney dialysis due to high blood pressure and diabetes, and to delay the progression of emphysema. The company also conducts basic research to find the genes which cause different diseases, and clinical research to test protocols which look promising for improving patient outcomes. The value of a single disease gene was estimated at $40-80 million by Daniel Cohen of Genset in 1999.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to,""should,""could,""may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether subsequent research confirms that the genes we've found are truly linked to common cancers, (b) whether Daniel Cohen was right that each disease gene will be worth $40-80 million, and (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed, Inc.
CONTACT: David W. Moskowitz MD, CEO of GenoMed, Inc., +1-314-983-9933, ordwmoskowitz@genomed.com
Web site: http://www.genomedics.com/
Source: PRNewswire-FirstCall
Related Articles
- Gene Silencing In Lung Cancer
- Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted By TorreyPines Therapeutics
- Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
- Pancreatic Cancer/Periodontal Link ID'D
- Dual Gene Therapy Suppresses Lung Cancer in Preclinical Test
- The Cancer Cure Coalition Supports the Nomination of Dr. Andrew Von Eschenbach As Commissioner of the U.S. FDA and Calls for the Approval of Advexin, a New Gene Therapy Treatment for Cancer
- One Cigarette a Day Can Treble the Risk of Heart Disease or Lung Cancer
- Multiple Genetic Processes Result in Heterogeneous Rates of Evolution Within the Major Cluster Disease Resistance Genes in Lettuce(W)
- University of Pittsburgh; A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer
- Follicular Thyroid Carcinoma; A cell-mediated approach to sFlt-1 gene therapy targets thyroid cancer
 |
 |
User Comments (0)
RSS Feeds